CD19-directed Antibody Interactions
- Name
- CD19-directed Antibody Interactions
- Accession Number
- DBCAT004331
- Description
Not Available
- Drugs
Drug Drug Description Blinatumomab An antineoplastic antibody used to treat CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in relapsed and refractory patients, as well as those in first or second complete remission with minimal residual disease (MRD). - Drugs & Drug Targets
Drug Target Type Blinatumomab B-lymphocyte antigen CD19 target Blinatumomab T-cell surface glycoprotein CD3 delta chain target